We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+32.17%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.01B
AUM Growth
+$300M
Cap. Flow
-$394M
Cap. Flow %
-7.86%
Top 10 Hldgs %
36.48%
Holding
142
New
15
Increased
17
Reduced
27
Closed
32

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$105M
2
BIIB icon
Biogen
BIIB
+$66.5M
3
ELV icon
Elevance Health
ELV
+$65.4M
4
SRRK icon
Scholar Rock
SRRK
+$27.5M
5
ARGX icon
argenx
ARGX
+$24.2M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$115M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
3
BAX icon
Baxter International
BAX
+$84.5M
4
CI icon
Cigna
CI
+$66.2M
5
ABBV icon
AbbVie
ABBV
+$49.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Industrials 1.01%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
126
Madrigal Pharmaceuticals
MDGL
$12.5B
– –
-253,309
Closed -$37M
MLTX icon
127
MoonLake Immunotherapeutics
MLTX
$1.58B
– –
-117,000
Closed -$6.67M
RLAY icon
128
Relay Therapeutics
RLAY
$3.95B
– –
-501,966
Closed -$4.22M
SYBX
129
DELISTED
Synlogic
SYBX
– –
-401,998
Closed -$1.13M
TARA icon
130
Protara Therapeutics
TARA
$218M
– –
-772,584
Closed -$1.29M
TDOC icon
131
Teladoc Health
TDOC
$1.69B
– –
-110,000
Closed -$2.04M
VTYX
132
DELISTED
Ventyx Biosciences
VTYX
– –
-340,384
Closed -$11.8M
XNCR icon
133
Xencor
XNCR
$1.44B
– –
-19,142
Closed -$386K
CUTR
134
DELISTED
Cutera, Inc.
CUTR
– –
-603,100
Closed -$3.63M
KRTX
135
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-14,000
Closed -$2.37M
MRTX
136
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-100,000
Closed -$4.36M
MRTX
137
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-1,959,050
Closed -$85.3M
SGEN
138
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-50,000
Closed -$10.6M
SGEN
139
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-42,600
Closed -$9.04M
HARP
140
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-62,121
Closed -$250K
HZNP
141
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-266,400
Closed -$30.8M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2023 Portfolio in Review

As of Q4 2023, OrbiMed held 142 positions worth $5.01B, up 6.4% from $4.71B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed withdrew a net $394M in Q4 2023, closing 32 positions and reducing 27 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, OrbiMed opened a new position in Elevance Health worth $66.7M.

  • OrbiMed's largest Q4 2023 buy was Elevance Health: 141,500 shares worth $66.7M.
  • OrbiMed added most to Eli Lilly in Q4 2023, an estimated $105M increase.
  • OrbiMed's biggest Q4 2023 reduction was Humana, cutting an estimated $115M.
  • OrbiMed fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $85.3M.
  • OrbiMed's ten largest holdings make up 36% of its $5.01B portfolio in Q4 2023.
  • OrbiMed opened 15 new positions and closed 32 in Q4 2023.
  • OrbiMed's portfolio value rose 6.4% quarter-over-quarter to $5.01B.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.